Postmarket Drug Safety Information for Patients and Providers > Approved Risk Evaluation and Mitigation Strategies (REMS)
Approved Risk Evaluation and Mitigation Strategies (REMS)
The Food and Drug Administration Amendments Act of 2007 gave FDA the authority to require a Risk Evaluation and Mitigation Strategy (REMS) from manufacturers to ensure that the benefits of a drug or biological product outweigh its risks. Additional REMS Information.
The three tables below provide separate lists for:
Currently Approved Individual REMS
Currently Approved Single Shared System REMS
-- Extended-Release and Long-Acting (ER/LA) Opioid Analgesics REMS
-- Isotretinoin iPLEDGE REMS
-- Mycophenolate REMS
-- Rosiglitazone REMS New! -- Transmucosal Immediate-Release Fentanyl (TIRF) Products REMS
Released REMS
Currently Approved Individual REMS
Product
Application
Date REMS Approved
REMS Components
(All REMS include timetable for assessment)
Actemra (tocilizumab) Injection (PDF - 2MB)
BLA 125276/49
1/8/2011;
modified 4/15/2011, 6/20/2012, 10/11/2012
communication plan
Adasuve (loxapine) Inhalation Powder (PDF - 3.5MB)
NDA 22-549
12/21/2012
communication plan, elements to assure safe use, implementation system
Ampyra (dalfampridine) Extended-Release Tablets (PDF - 124KB)
NDA 22-250/S-004
1/22/2010; modified 11/17/2011; 7/20/2012
communication plan
Androgel (testosterone) Gel (PDF - 28KB)
NDA 21-015/S-032
9/18/2009; modified 3/10/2011, 11/30/2011
medication guide
Androgel (testosterone) 1.62% Gel (PDF - 65KB)
NDA 22-309/S-001
4/29/2011; modified 9/7/2012
medication guide
Aranesp (darbepoetin alfa) Injection (PDF - 11MB)
BLA 103951/5285
2/16/2010; modified 6/24/2011, 5/31/2012
medication guide, communication plan,
elements to assure safe use,
implementation system
Axiron (testosterone) Topical Solution (PDF - 37KB)
NDA 22-504/S-002
11/23/2010; modified 3/31/2011
medication guide
Brilinta (ticagrelor) Tablets (PDF - 238KB) Updated!
NDA 22-433/S-006
7/20/2011; modified 1/24/2013
medication guide, communication plan
Bydureon (exenatide) Extended-Release for Injectable Suspension (PDF - 116KB)
NDA 22-200
1/27/2012
communication plan
Caprelsa (vandetanib) Tablets (PDF - 6MB)
NDA 22-405/S-001
4/6/2011; modified
6/22/2011
medication guide, communication plan, elements to assure safe use, implementation system
Chantix (varenicline) Tablets (PDF - 17KB)
NDA 21-928/S-019, S-020, S-21
10/19/2009; modified 4/22/2010, 7/22/2011
medication guide
Darvon Capsules, Darvon-N Tablets, and Darvocet-N (propoxyphene) Tablets
NDA 10-997/S-051, S-052; 16-062/S-041, S-042; 17-122/S-061, S-062
9/25/2009
medication guide
Eliquis (apixaban) Tablets (PDF - 280KB)
NDA 202155
12/28/2012
communication plan
Entereg (alvimopan) Capsules (PDF - 1090KB)
NDA 21-775/S-007
5/20/2008
modified 2/5/2009, 9/25/2012
communication plan, elements to assure safe use, implementation system
Epogen/Procrit (epoetin alfa) Injection (PDF - 11MB)
BLA 103234/5281
2/16/2010; modified 6/24/2011, 5/31/2012
medication guide, communication plan, elements to assure safe use, implementation system
Extraneal (icodextrin) Intraperitoneal Solution (PDF - 2411KB)
NDA 21-321/S-020, S-021
3/8/2011
medication guide, elements to assure safe use, implementation system
Foradil (formoterol fumarate) Inhalation Powder (PDF - 306KB)
NDA 20-831/S-022
5/18/2011
communication plan
Forteo (teriparatide [rDNA origin]) Injection (PDF - 254KB)
NDA 21-318/S-027
7/22/2009; modified 3/13/2012
medication guide, communication plan
Fortesta (testosterone) Gel (PDF - 30KB)
NDA 21-463
12/29/2010
medication guide
Gattex (teduglutide [rDNA origin]) Injection (PDF - 946KB)
NDA 203441
12/21/2012
communication plan, elements to assure safe use
Gilenya (fingolimod) Capsules (PDF - 274KB)
NDA 22-527/S-005
9/21/2010; modifed 3/1/2012
communication plan
H.P. Acthar Gel (repository corticotropin) Injection (PDF - 56KB)
NDA 22-432
10/15/2010
medication guide
Juxtapid (lomitapide) Capsules (PDF - 2.5MB)
NDA 203858
12/21/2012
elements to assure safe use, implementation system
Kalbitor (ecallentide) Injection (PDF - 205KB)
BLA 125277/50
12/1/2009; modified 4/5/2011, 8/17/2011, 4/24/2012
communication plan
Krystexxa (pegloticase) Injection (PDF - 248KB)
BLA 125293/34, 40
9/14/2010; modified 10/19/2010, 4/16/2012
communication plan
Kynamro (mipomersen sodium) (PDF - 15MB) New!
NDA 203568
1/29/2013
elements to assure safe use, implementation system
Letairis (ambrisentan) Tablets (PDF - 2MB)
NDA 22-081/S-022
5/29/2009; modified 7/1/2009,
8/5/2009, 8/24/2010, 10/13/2010, 3/3/2011, 2/15/2012, 10/19/2012
medication guide, elements to assure safe use, implementation system
Lotronex (alosetron hydrochloride) Tablets (PDF - 18MB)
NDA 21-107/S-014
9/2/2010
medication guide, elements to assure safe use, implementation system
Lumizyme (alglucosidase alfa) (PDF - 848KB)
BLA 125291/79
5/24/2010; modified 9/12/2011, 7/16/2012
communication plan, elements to assure safe use, implementation system
Meridia (subutramine hydrochloride) Capsules
NDA 20-632/S-034, S-035
8/4/2010
medication guide
Metoclopramide Oral Solution (PDF - 31KB)
ANDA 74-703/S-007
9/15/2009
medication guide
Metoclopramide Oral Solution (PDF - 24KB)
ANDA 72-744/S-011
9/15/2009
medication guide
Metoclopramide Oral Solution (PDF - 24KB)
ANDA 71-402/S-008
9/16/2009
medication guide
Mifeprex (mifepristone) Tablets (PDF - 205KB)
NDA 20-687/S-014
6/8/2011
medication guide, elements to assure safe use, implementation system
Multaq (dronedarone) Tablets (PDF - 111KB)
NDA 22-425/S-016, S-017, S-018
7/1/2009; modified 2/11/2011, 8/5/2011, 6/13/2012, 9/7/2012
medication guide, communication plan
Nplate (romiplostim) for Subcutaneous Injection (PDF - 45KB)
BLA 125268/77
8/22/2008; modified 8/14/2009, 3/23/2010, 7/29/2011, 12/6/2011
communication plan
Nulojix (belatacept) (PDF - 946KB)
BLA 125288
6/15/2011
medication guide, communication plan
Omontys (peginesatide) Injection (PDF - 165KB)
NDA 202799
3/27/2012
communication plan
Potiga (ezogabine) Tablets (PDF - 524KB)
NDA 22-345/S-001
6/10/2011; modified 3/19/2012
communication plan
Prolia (denosumab) Injection (PDF - 129KB)
BLA 125320/53
6/1/2010; modified 9/16/2011, 5/10/2012
medication guide, communication plan
Promacta (eltrombopag) Tablets (PDF - 225KB)
NDA 22-291/S-006
11/20/2008; modified 3/5/2010, 2/25/2011, 12/6/2011
communication plan
Qsymia (phentermine and topiramate) Extended-Release Capsules (PDF - 3MB)
NDA 22-580/S-001
7/17/2012; modified 11/1/2012
medication guide, elements to assure safe use, implementation system
Revlimid (lenalidomide) Capsules (PDF - 2523KB)
NDA 21-880/S-031
8/3/2010; modified 5/9/2012
medication guide, elements to assure safe use, implementation system
Sabril (vigabatrin) Oral Solution and Tablets (PDF - 1.5MB)
NDA 22-006/S-006; 20-427/S-005
8/21/2009; modified 1/18/2011, 12/11/2012
medication guide, communication plan, elements to assure safe use, implementation system
Soliris (eculizumab) Injection (PDF - 3MB)
BLA 125166/172
6/4/2010; modified 9/23/2011
medication guide, elements to assure safe use
Stelara (ustekinumab) Injection (PDF - 347KB)
BLA 125261/63
9/25/2009; modified 12/30/2009, 10/20/2010, 5/2/2012
communication plan
Suboxone (buprenorphine and naloxone) Sublingual Film (PDF - 960KB)
NDA 22-410
8/30/2010
medication guide, elements to assure safe use, implementation system
Suboxone (buprenorphine and naloxone) Sublingual Tablets (PDF - 455KB)
NDA 22-733/S-007, S-008
12/22/2011
medication guide, elements to assure safe use, implementation system
Subutex (buprenorphine) Sublingual Tablets (PDF - 467KB)
NDA 20-732/S-006, S-007
12/22/2011
medication guide, elements to assure safe use, implementation system
Tapentadol Tablets (PDF - 222KB)
NDA 22-304
11/20/2008
medication guide
Tasigna (nilotinib) Capsules (PDF - 4MB)
NDA 22-068/S-008, S-009
3/15/2010; modified 6/17/2010, 1/14/2011, 10/26/2011, 11/18/2011
medication guide, communication plan
Testim (testosterone) Gel (PDF - 35KB)
NDA 21-454/S-014
9/18/2009; modified 11/22/2011
medication guide
Testosterone Gel (PDF - 13KB)
NDA 202763
2/14/2012
medication guide
Thalomid (thalidomide) Capsules (PDF - 5402KB)
NDA 20-785/S-039
8/3/2010
medication guide, elements to assure safe use, implementation system
Tikosyn (dofetilide) Capsules (PDF - 2MB)
NDA 20-931/S-003
7/11/2011
medication guide, elements to assure safe use, implementation system
Tracleer (bosentan) Tablets (PDF - 1000KB)
NDA 21-290/S-018
8/7/2009; modified 2/19/2010
medication guide, elements to assure safe use, implementation system
Truvada (emtricitabine and tenofovir disoproxil fumarate) Tablets (PDF - 9MB)
NDA 21-752/S-030
7/16/2012
medication guide, elements to assure safe use
Tysabri (natalizumab) Intravenous Injection (PDF - 65KB)
BLA 125104/576
10/7/2011; modified 1/20/2012
medication guide, elements to assure safe use, implementation system
Vibativ (telavancin) Injection (PDF - 133KB)
NDA 22-110/S-002
9/11/2009; modified 7/27/2011
medication guide, communication plan
Victoza (liraglutide) Injection (PDF - 1025KB)
NDA 22-341/S-004
1/25/2010; modified 5/18/2011
communication plan
Vivitrol (naltrexone) Extended-Release Injectable Suspension (PDF - 27KB)
NDA 21-897/S-015
3/22/2010; modified 10/12/2010
medication guide
Xarelto (rivaroxaban) Tablets (PDF - 438KB)
NDA 202439/S-005
11/4/2011; modified 7/12/2012
communication plan
Xeljanz (tofacitinib) Tablets (PDF - 161KB)
NDA 203214
11/6/2012
medication guide, communication plan
Xenazine (tetrabenazine) Tablets (PDF - 1011KB)
NDA 21-894/S-007
8/15/2008; modified 12/1/2009, 5/4/2011, 8/17/2012
communication plan
Xiaflex (collagenase clostridium histolyticum) Injection (PDF - 2MB)
BLA 125338/40
2/2/2010; modifed 2/24/2012
communication plan
Yervoy (ipilimumab) Injection (PDF - 3MB)
BLA 125377/16
3/25/2011; modified 2/16/2012
communication plan
Zyban (bupropion hydrochloride) Sustained-Release Tablets (PDF - 19KB)
NDA 20-711/S-034
2/26/2010
medication guide
Zyprexa Relprevv (olanzapine) Extended-Release Injection (PDF - 3.5MB)
NDA 22-173/S-008, S-010, S-014
12/11/2009; modified 7/8/2010, 8/3/2012
medication guide, communication plan, elements to assure safe use, implementation system
Currently Approved Single Shared System REMS
Name of Shared System REMS (and included products)
Date REMS Approved
REMS Components
(All REMS include timetable for assessment)
Extended-Release and Long-Acting Opioid Analgesics REMS (PDF - 1.3MB)
List of extended-release and long-acting opioid products required to have the REMS
7/9/2012; modified 8/28/2012
medication guide,
elements to assure safe use
Isotretinoin iPLEDGE REMS (PDF - 315KB)
List of application numbers and sponsors (PDF - 15KB) (updated 6/7/2012)
10/22/2010
medication guide,
elements to assure safe use,
implementation system
Mycophenolate REMS (PDF - 5MB)
List of application numbers and sponsors (PDF - 59KB)
Cellcept (mycophenolate mofetil)
Myfortic (mycophenolic acid)
Generic forumations of mycophenolate mofetil
Generic formulations of mycophenolic acid
9/25/2012
medication guide,
elements to assure safe use
Rosiglitazone REMS (PDF - 1.2MB) New!
List of application numbers and sponsors (PDF - 9KB)
Avandamet
Avandaryl
Avandia
Generic rosiglitazone products
1/25/2013
medication guide, elements to assure safe use, implementation system
Transmucosal Immediate-Release Fentanyl (TIRF) Products (PDF - 900KB)
List of application numbers and sponsors (PDF - 15KB)
Abstral (fentanyl) Sublingual Tablets
Actiq (fentanyl citrate) Oral Transmucosal Lozenge and the generic equivalents
Fentora (fentanyl citrate) Buccal Tablets
Lazanda (fentanyl) Nasal Spray
Onsolis (fentanyl) Buccal Soluble Film
Subsys (fentanyl) Sublingual Spray
12/28/2011; modified 6/5/2012
medication guide,
elements to assure safe use,
implementation system
Released REMS
Product
Date Released from REMS Requirement
Actonel (risedronate sodium) Tablets
8/22/2011
Actonel with Calcium (risedronate sodium and calcium carbonate) Tablets
8/22/2011
Actoplus Met (pioglitazone hydrochloride and metformin hydrochloride) Tablets
5/17/2012
Actoplus Met XR (pioglitazone and metformin) Extended-Release Tablets
5/17/2012
Actos (pioglitazone hydrochloride) Tablets
5/17/2012
Advair Diskus (fluticasone propionate and salmeterol xinafoate inhalation powder)
8/9/2012
Advair HFA (fluticasone propionate and salmeterol xinafoate inhalation powder)
8/9/2012
Aplenzin (buproprion hydrobromide) Extended-Release Tablets
4/29/2011
Arcapta Neohaler (indacaterol maleate) Inhalation Powder
12/18/2012
Atelvia (risedronate sodium) Delayed-Release Tablets
8/22/2011
Avelox (moxifloxacin) Tablets and I.V. Solution
8/3/2011
Banzel (rufinamide) Tablets and Oral Suspension
6/10/2011
Boniva (ibandronate sodium) Injection
7/1/2011
Boniva (ibandronate sodium) Tablets
7/1/2011
Botox/Botox Cosmetic (onabotulinumtoxinA) Injection
7/16/2012
Brovana (arformoterol tartrate) Inhalation Solution
8/9/2012
Byetta (exanatide) Injection
8/5/2011
Cambia (diclofenac potassium) Oral Solution
7/20/2011
Carbatrol (carbamazepine) Extended-Release Capsules
8/22/2011
Celontin (methsuximide) Capsules
6/15/2011
Cimzia (certolizumab pegol) Lyophilized powder for solution for subcutaneous injection
7/26/2011
Cipro (ciprofloxacin) Tablets, Oral Suspension, I.V. Solution , and Extended-Release Tablets
8/3/2011
Colcrys (colchicine) Tablets
7/20/2011
Colcrys (colchicine) Tablets
7/20/2011
Colcrys (colchicine) Tablets
7/20/2011
Copegus (ribavirin) Tablets
5/9/2011
Creon (pancrelipase) Delayed-Release Capsules
5/9/2011
Dilantin (phenytoin) Oral Suspension
5/27/2011
Duetact (pioglitazone hydrochloride and glimepiride) Tablets
5/17/2012
Dulera (mometasone furoate and formoterol fumarate) Inhalation Aerosol
11/27/2012
Dysport (abobotulinumtoxinA) Injection
5/22/2012
Edluar (zolpidem tartrate) Sublingual Tablets
8/10/2011
Effient (prasugrel) Tablets
3/23/2012
Enbrel (etanercept) for Subcutaneous Injection
8/10/11
Epzicom (abacavir sulfate and lamivudine) Tablets
5/13/2011
Equetro (carbamazepine) Extended-Release Capsules
1/27/2012
Extavia (interferon beta-1b)
6/22/2011
Factive (gemifloxacin) Tablets
8/4/2011
Fosamax (alendronate sodium) Oral Solution and Tablets
7/1/2011
Fosamax Plus D (alendronate sodium and cholecalciferol) Tablets
7/1/2011
Gabitril (tiagabine hydrochloride) Tablets
1/25/2012
Gralise (gabapentin) Tablets
4/28/2011
HalfLytely Bisacodyl Bowel Prep Kit (bisacodyl, polyethylene glycol 3500, potassium chloride, sodium bicarbonate, sodium chloride)
7/6/2011
Humira (adalimumab) Injection
12/13/2011
Infergen (interferon alfacon-1)
6/1/2011
Intron A (interferon alfa-2b)
5/13/2011
Invirase (saquinavir mesylate) Capsules and Tablets
5/26/2011
Janumet (sitagliptin/metformin) Tablets
4/14/2011
Januvia (sitagliptin) Tablets
4/14/2011
Kaletra (lopinavir and ritonavir) Tablets and Oral Solution
5/6/2011
Keppra, Keppra XR (levetiracetam) Tablets, Extended-Release Tablets, Oral Solution, and Injection
8/10/2011
Ketek (telithromycin) Tablets
6/20/2011
Klonopin (clonazepam) Tablets and Orally Disintegrating Tablets
11/29/2011
Lamictal (lamotrigine) Tablets, Chewable Dispersible Tablets, and Orally Disintegrating Tablets (ODT)
5/31/2011
Lamictal XR (lamotrigine) Extended-Release Tablets
4/25/2011
Lariam (mefloquine hydrochloride) Tablets
4/29/2011
Levaquin (levofloxacin) Tablets, Injection, and Oral Solution
10/7/2011
Lyrica (pregabalin) Capsules and Oral Solution
4/26/2011
Metoclopramide Oral Solution (ANDA 73-680)
3/14/2012
Metozolv ODT (metoclopramide hydrochloride) Orally Disintegrating Tablets
8/22/2011
Morphine Sulfate Oral Solution
10/18/2011
Myobloc (rimabotulinumtoxinB) Injection
6/13/2012
Mysoline (primidone) Tablets
8/10/2011
Neurontin (gabapentin) Capsules, Tablets, and Oral Solution
8/10/2011
Noroxin (norfloxacin) Tablets
9/8/2011
Nuvigil (armodafinil) Tablets
1/13/2012
Oleptro (trazadone hydrochloride) Extended-Release Tablets
5/11/2011
Osmoprep (sodium phosphate, dibasic anhydrous and sodium phosphate, monobasic, monohydrate) Tablets
12/9/2011
Oxycodone Hydrochloride Oral Solution
1/25/2012
Pancreaze (pancrelipase) Delayed-Release Capsules
6/20/2011
Peganone (ethotoin) Tablets
5/31/2011
Pegasys (peginterferon alfa-2a)
5/9/2011
PegIntron (peginterferon alfa-2b)
5/13/2011
PegIntron Rebetol Combopack (peginterferon alfa-2b, Redipen Single-dose Delivery System and Rebetol ribavirin)
8/18/2009
Pennsaid (diclofenac sodium) Topical Solution
7/14/2011
Plavix (clopidogrel bisulfate) Tablets
5/3/2011
Perforomist (formoterol fumarate) Inhalation Solution
9/25/2012
Pradaxa (dabigatran etexilate mesylate) Capsules
4/5/2011
Propylthiouracil (propylthiouracil) Tablets
7/27/2011
Proquin XR (ciprofloxacin) Extended-Release Tablets
8/15/2011
Provigil (modafinil) Tablets
1/13/2012
Qualaquin (quinine sulfate) Capsules
5/22/2012
Rapamune (sirolimus) Oral Solution and Tablets
6/6/2011
Rebetol (ribivarin) Capsules and Oral Solution
4/19/2011
Reclast (zoledronic acid) Injection
8/15/2011
Reglan ODT (metoclorpramide hydrochloride) Orally Disintegrating Tablets
8/2/2011
Reglan (metoclopramide hydrochloride) Tablets
8/2/2011
Regranex (becaplermin)
4/30/2012
Remicade (infliximab) Vial
8/1/2011
Roferon-A Interferon (alfa-2a, recombinant) Injection
6/16/2011
Rozerem (ramelteon) Tablets
8/4/2011
Samsca (tolvaptan) Tablets
9/14/2012
Savella (milnacipran hydrochloride) Tablets
4/26/2011
Serevent Diskus (salmeterol xinafoate) Inhalation Powder
8/9/2012
Seroquel (quetiapine) Tablets
11/9/2011
Seroquel XR (quetiapine) Extended-Release Tablets
11/9/2011
Silenor (doxepin) Tablets
10/30/2011
Simponi (golimumab) Injection
3/17/2011
Sucraid (sacrosidase) Oral Solution
12/9/2010
Suprep Bowel Prep Kit (sodium sulfate, potassium sulfate, and magnesium sulfate) Oral Solution
7/6/2011
Sutent (sunitinib) Capsules
5/19/2011
Symbicort (budesonide and formoterol) Inhalation Aerosol
7/23/2012
Symbyax (olanzapine and fluoxetine) Capsules
6/21/2011
Tegretol and Tegretol-XR (carbemazepine) Tablets, ChewableTablets, Suspension, and Extended-Release Tablets
10/30/2011
Topamax (topiramate) Tablets and Sprinkle Capsules
6/27/2011
Tranxene (clorazepate dipotassium) Tablets
7/19/2011
Treximet (sumatriptan succinate and naproxen sodium) Tablets
9/23/2011
Trileptal (oxcarbazepine) Tablets and Suspension
10/30/2011
Trilipix (fenofibric acid) Delayed-Release Capsules
9/30/2011
Trizivir (abacavir sulfate, lamivudine, and zidovudine) Tablets
5/13/2011
Tyzeka (telbivudine) Oral Solution
5/5/2011
Tyzeka (telbivudine) Tablets
5/5/2011
Venlafaxine hydrochloride Extended- Release Tablets
7/31/2012
Videx, Videx EC (didanosine) Delayed-Release Capsules and Oral Solution
5/10/2011
Viibryd (vilazodone hydrochloride) Tablets
6/29/2011
Vimpat (lacosamide) Injection, Oral Solution, and Tablets
8/10/2011
Viramune (nevirapine) Tablets, Oral Suspension, and Extended-Release Tablets
5/6/2011
Visicol (sodium phosphate, dibasic anhydrous and sodium phosphate, monobasic, monohydrate)Tablets
12/9/2011
Votrient (pazopanib) Tablets
4/21/2011
Wellbutrin, Wellbutrin SR (bupropion hydrochloride) Tablets and Sustained-Release Tablets
8/2/2012
Wellbutrin XL (bupropion hydrochloride) Extended-Release Tablets
8/2/2012
Xeomin (incobotulinumtoxinA) Injection
7/16/2012
Xolair (omalizumab) Injection
12/22/2011
Zarontin (ethosuximide) Capsules
6/15/2011
Zenpep (pancrelipase) Delayed-Release Capsules
6/10/2011
Zerit (stavudine) Capsules and Oral Solution
5/11/2011
Ziagen (abacavir sulfate) Tablets and Oral Solution
5/13/2011
Zipsor (diclofenac potassium) Capsules
5/4/2011
Zolpimist (zolpidem tartrate) Oral Spray
9/28/2011
Zonegran (zonisamide) Capsules
5/27/2011
Zortress (everolimus) Tablets
5/2/2012
Zyprexa, Zyprexa Zydis (olanzapine) Tablets
6/21/2011
-
More Information on Single Shared System REMS
Single Shared System REMS for Mycophenolate-containing Medicines: Questions and Answers
9/25/2012
REMS for Extended-Release and Long-Acting Opioid Drugs
Single Shared System REMS for TIRF (transmucosal immediate-release fentanyl) Products
12/29/2011
-
-
Additional REMS Resources
REMS Assessments: Social Science Methodologies to Assess Goals Related to Knowledge: Public Workshop, 6/7/2012
FDA Issue Paper on REMS Assessments, June 7, 2012 (PDF - 96KB)
Guidance for Industry: Medication Guides — Distribution Requirements and Inclusion in REMS (PDF - 91KB)
Final version (11/2011)
Questions and Answers on Draft Guidance for Industry: Medication Guides - Distribution Requirements and Inclusion in REMS
3/2011
Format and Content of Proposed REMS, REMS Assessments, and Proposed REMS Modifications (PDF - 316KB)
Guidance for Industry (9/2009)